Drug Approval | May 20, 2023
Strides Puducherry facility receives EIR from USFDA
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Venlafaxine HCl extended-release capsules are indicated for the treatment of: Major Depressive Disorder
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
Farxiga is expected to have such a strong influence on the market due to the impressive results
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
To enhance housing and enclosure design and performance for the Asia Pacific medical devices market, Kraiburg TPE offers the Thermoplast H HC/AP and HC/AD1/AP series
The facility will have a capacity to manufacture upto 3 million tubes monthly
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
Subscribe To Our Newsletter & Stay Updated
